

## ASX Announcement

### IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD

---

**SYDNEY, Australia, 1 June 2022:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce the appointment of Dr. Yanghee Woo, MD, FACS, Surgical Oncologist and Associate Professor of Surgery, City of Hope to the Company's Scientific Advisory Board (SAB).

Dr. Woo is an internationally recognised surgeon-scientist with clinical expertise in robotic surgery and gastric cancer. She holds several key positions at City of Hope including Director of GI Minimally Invasive Therapies Program, Vice Chair of International Affairs and is also a Visiting Professor at Xiangya Medical School, China.

In addition to her clinical and teaching experience, Dr. Woo is currently researching gastric cancer inception and viral oncolytic therapy based on the CF33-platform. Dr. Woo is part of the team that created a chimeric orthopoxvirus, CF33-hNIS-antiPDL1, which has exhibited strong potential in targeting solid tumours and the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC).

Previous to commencing at the Department of Surgery at City of Hope in 2015, Dr. Woo held various positions at Columbia University Medical Center's (CUMU) Pancreas Center where she was Assistant Professor of Surgery and later Director of Center for Global Excellence in Gastric Cancer Care.

Dr. Woo received her Medical Doctorate from Drexel University Medical School and completed the Health Careers Program at Harvard University. She completed a general surgery residency at CUMC, a research fellowship at Memorial Sloan Kettering Cancer Center and a clinical fellowship at Severance Hospital, Yonsei University, Seoul.

#### *Resignation of Chief Medical Officer Dr Steven Cha*

Imugene also announces today that its Chief Medical Officer, Dr. Steven Cha, is regretfully resigning from his position due to family reasons. The Company wishes him the very best and will announce a replacement in due course.

*Imugene's Managing Director & CEO Leslie Chong said:*

“Imugene is proud to have yet another world class physician and scientist join our Scientific Advisory Board. Dr. Woo will enhance the strength of our already impressive medical and scientific team and we look forward to leveraging her expertise as we develop our clinical pipeline.

“We appreciate the contributions Dr. Cha has made to Imugene over the last several months and wish him the very best in his future endeavours.”

For more information please contact:

**Leslie Chong**

Managing Director and Chief Executive Officer

**Investor Enquires**

investor@imugene.com

**Media Enquires**

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

**About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumors. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-

oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*

*Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*